Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)00143-6 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1370-1379 ◽

Author(s):

Marinus H J van Oers ◽

Kazimierz Kuliczkowski ◽

Lukáš Smolej ◽

Mario Petrini ◽

Fritz Offner ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793562618 ◽

2019 ◽

Author(s):

Corrado Girmenia

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Phase 3 ◽

Previously Treated

Download Full-text

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30051-1 ◽

2016 ◽

Vol 17 (7) ◽

pp. 928-942 ◽

Author(s):

Barbara Eichhorst ◽

Anna-Maria Fink ◽

Jasmin Bahlo ◽

Raymonde Busch ◽

Gabor Kovacs ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793538186 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Phase 3 ◽

Previously Treated

Download Full-text

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30019-4 ◽

2017 ◽

Vol 4 (3) ◽

pp. e114-e126 ◽

Author(s):

Jeffrey A Jones ◽

Tadeusz Robak ◽

Jennifer R Brown ◽

Farrukh T Awan ◽

Xavier Badoux ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Phase 3 ◽

Previously Treated

Download Full-text

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study

The Lancet Haematology ◽

10.1016/s2352-3026(17)30235-1 ◽

2018 ◽

Vol 5 (2) ◽

pp. e82-e94 ◽

Author(s):

Caroline Dartigeas ◽

Eric Van Den Neste ◽

Julie Léger ◽

Hervé Maisonneuve ◽

Christian Berthou ◽

...

Keyword(s):

Elderly Patients ◽

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Phase 3 ◽

Rituximab Maintenance

Download Full-text

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

10.1016/s0140-6736(10)61381-5 ◽

2010 ◽

Vol 376 (9747) ◽

pp. 1164-1174 ◽

Cited By ~ 1245

Author(s):

M Hallek ◽

K Fischer ◽

G Fingerle-Rowson ◽

AM Fink ◽

R Busch ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30443-5 ◽

2020 ◽

Vol 21 (9) ◽

pp. 1188-1200 ◽

Author(s):

Othman Al-Sawaf ◽

Can Zhang ◽

Maneesh Tandon ◽

Arijit Sinha ◽

Anna-Maria Fink ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Download Full-text

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

The Lancet Haematology ◽

10.1016/s2352-3026(20)30433-6 ◽

2021 ◽

Vol 8 (4) ◽

pp. e254-e266

Author(s):

Jeff P Sharman ◽

Danielle M Brander ◽

Anthony R Mato ◽

Nilanjan Ghosh ◽

Stephen J Schuster ◽

...

Keyword(s):

High Risk ◽

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Randomised Trial ◽

Download Full-text

Faculty Opinions recommendation of Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734628071.793582410 ◽

2021 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Line Treatment ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

10.1016/s0140-6736(15)60027-7 ◽

2015 ◽

Vol 385 (9980) ◽

pp. 1873-1883 ◽

Author(s):

Peter Hillmen ◽

Tadeusz Robak ◽

Ann Janssens ◽

K Govind Babu ◽

Janusz Kloczko ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Lymphocytic Leukaemia ◽

Phase 3 ◽

Open Label Phase

Download Full-text